Last updated: February 19, 2026
This analysis examines the current market position and future pricing trajectory for the drug identified by National Drug Code (NDC) 49884-0222. Data indicates a stable supply chain with consistent demand, supporting a projected price maintenance within the next 24 months.
What is NDC 49884-0222?
National Drug Code 49884-0222 identifies Diclofenac Sodium Topical Solution, 2%. This formulation is indicated for the topical treatment of the signs and symptoms of osteoarthritis of the knee and for the relief of mild to moderate pain [1]. It is a non-steroidal anti-inflammatory drug (NSAID) that works by reducing hormones that cause inflammation and pain in the body. The product is manufactured by Viatris Pharmaceuticals, Inc. [2].
Current Market Landscape
The market for topical diclofenac sodium solutions is characterized by a moderate number of therapeutic alternatives, primarily other NSAIDs (topical and oral), acetaminophen, and in some cases, prescription-strength topical agents. However, NDC 49884-0222 holds a specific position due to its formulation and established prescription history.
Key Market Participants
- Manufacturer: Viatris Pharmaceuticals, Inc.
- Primary Competitors (Topical NSAIDs):
- Diclofenac gel formulations (e.g., Voltaren Gel, manufactured by GlaxoSmithKline, with different NDC numbers).
- Ketoprofen topical formulations.
- Alternative Pain Relief:
- Oral NSAIDs (e.g., ibuprofen, naproxen).
- Acetaminophen.
- Topical analgesics (e.g., capsaicin creams, menthol rubs).
Distribution Channels
NDC 49884-0222 is primarily distributed through:
- Retail Pharmacies: Both independent and chain pharmacies dispense the product via prescription.
- Wholesale Distributors: Major pharmaceutical distributors supply the product to pharmacies and healthcare facilities.
- Mail-Order Pharmacies: Prescription fulfillment services also carry and dispense the drug.
Reimbursement and Payer Landscape
Reimbursement for NDC 49884-0222 is subject to individual health insurance plans. Coverage typically requires a prescription and may have specific criteria related to patient diagnosis and prior treatment history. Generic status generally leads to broader formulary acceptance compared to branded drugs, though co-pays and deductibles remain a factor for patient out-of-pocket costs [3]. Medicare Part D plans generally cover topical diclofenac sodium.
Demand and Usage Patterns
Demand for NDC 49884-0222 is driven by the prevalence of osteoarthritis, particularly in the aging population. The United States Centers for Disease Control and Prevention (CDC) reports that osteoarthritis affects over 32.5 million adults in the U.S. [4]. Knee osteoarthritis is a common cause of chronic pain and disability, making topical treatments like this solution a preferred option for many patients seeking localized pain relief with potentially fewer systemic side effects than oral medications.
Factors influencing demand:
- Demographics: Increasing age of the U.S. population.
- Osteoarthritis Prevalence: High and growing incidence rates.
- Patient Preference: Desire for localized pain relief and reduced systemic exposure.
- Prescriber Practices: Physician comfort and familiarity with prescribing topical diclofenac.
- Insurance Coverage: Extent of formulary placement and patient co-pays.
Pricing Analysis and Projections
The pricing of NDC 49884-0222 is influenced by manufacturing costs, wholesale margins, retail markups, and payer negotiations. As a generic product, price competition is a significant factor.
Current Pricing Benchmarks (as of Q4 2023/Q1 2024)
Pricing for NDC 49884-0222 can vary based on the pharmacy, geographic location, and insurance plan. However, general benchmarks for a 30-day supply (typically 150 mL bottle) are as follows:
- Wholesale Acquisition Cost (WAC): Approximately $40 - $60.
- Average Wholesale Price (AWP): Approximately $70 - $100.
- Patient Out-of-Pocket (Cash Price): Can range from $50 - $120, depending on pharmacy and discounts.
- Insured Patient Co-pay: Typically $10 - $30.
Note: These figures represent estimates and can fluctuate.
Factors Affecting Future Pricing
- Raw Material Costs: Fluctuations in the cost of diclofenac sodium and excipients could impact manufacturing expenses. However, for established generic drugs, these costs are generally stable.
- Manufacturing Capacity and Competition: Viatris has established manufacturing processes. The entry of new generic manufacturers for this specific NDC or formulation could increase price pressure. Currently, Viatris is the primary, if not sole, supplier for this specific NDC.
- Payer Policies and Rebates: Pharmaceutical benefit managers (PBMs) and insurance companies negotiate rebates with manufacturers. These negotiations can influence the net price of the drug to payers and, indirectly, its listed price.
- Generic Drug Pricing Trends: The overall trend for generic drugs is towards price stabilization or gradual decline, particularly for mature products with multiple manufacturers. However, for single-source generics, pricing power can be maintained longer.
- Regulatory Changes: Any changes in FDA regulations regarding manufacturing or labeling could affect costs, though significant shifts are not anticipated for this established product.
- Demand Shifts: A significant increase or decrease in osteoarthritis prevalence or a major shift towards alternative therapies could influence demand and pricing.
Price Projection for NDC 49884-0222 (Next 24 Months)
Based on current market conditions, the following price projection is made:
- Short-Term (Next 12 months): Expect minimal price fluctuations. The WAC is projected to remain within a 2-3% increase or decrease range, largely influenced by minor adjustments in manufacturing input costs or distribution fees. The AWP and cash prices will likely follow suit.
- Medium-Term (12-24 months): The price is projected to remain relatively stable. A slight downward pressure might emerge if competitor formulations gain significant market share, but this is unlikely to cause dramatic price drops unless a direct generic competitor with the same NDC emerges. A 0-2% annual price increase is anticipated, primarily to account for inflation and minor supply chain adjustments.
Table 1: Projected Price Range for NDC 49884-0222 (Next 24 Months)
| Metric |
Current Range (Q4 2023/Q1 2024) |
Projection (Next 12 Months) |
Projection (12-24 Months) |
| WAC ($) |
40 - 60 |
40.80 - 61.80 |
41.62 - 63.04 |
| AWP ($) |
70 - 100 |
71.40 - 102.00 |
72.83 - 104.04 |
| Patient Cash Price ($) |
50 - 120 |
51.00 - 122.40 |
52.02 - 124.85 |
Assumptions:
- No significant new generic competition for this specific NDC emerges.
- No major disruptive therapeutic advancements that render topical diclofenac obsolete.
- Stable raw material and manufacturing costs.
- Continued reimbursement by major payers.
Risk Factors and Considerations
- Emergence of Direct Generic Competition: While Viatris is currently the primary supplier for this NDC, the possibility of another manufacturer obtaining approval for the same formulation and NDC exists, which would significantly increase price competition and drive prices down.
- Therapeutic Substitution: The development and adoption of novel pain management therapies, particularly those with superior efficacy, safety profiles, or convenience, could reduce demand for topical diclofenac.
- Formulation Patent Expiration: While the active pharmaceutical ingredient (API) is off-patent, specific formulation patents can exist. However, for a 2% topical solution, it is unlikely that such patents are currently acting as a significant barrier to generic entry at the NDC level if Viatris is the sole holder.
- Manufacturer Issues: Production disruptions, quality control issues, or voluntary recalls by Viatris could lead to temporary shortages and price spikes, though this is a low-probability event for established products.
Key Takeaways
NDC 49884-0222, Diclofenac Sodium Topical Solution 2%, manufactured by Viatris Pharmaceuticals, Inc., exhibits a stable market position driven by the prevalence of osteoarthritis. Current pricing reflects its status as a generic drug with limited direct competition at the NDC level. The projected price trajectory over the next 24 months indicates minimal fluctuation, with a slow upward drift likely tied to inflation and minor supply chain adjustments. Key risks include the potential emergence of direct generic competition and the introduction of superior alternative therapies.
Frequently Asked Questions
- Is NDC 49884-0222 a branded or generic drug?
NDC 49884-0222 is a generic drug, specifically Diclofenac Sodium Topical Solution, 2%.
- What is the primary indication for this drug?
The primary indication is the topical treatment of the signs and symptoms of osteoarthritis of the knee and for the relief of mild to moderate pain [1].
- Who is the manufacturer of NDC 49884-0222?
Viatris Pharmaceuticals, Inc. is the manufacturer identified for NDC 49884-0222 [2].
- Are there other Diclofenac Sodium products with different NDCs?
Yes, there are numerous other Diclofenac Sodium products available, including different strengths, formulations (e.g., gels, patches), and manufacturers, each with unique NDCs. NDC 49884-0222 specifically identifies the 2% topical solution.
- What factors are most likely to cause a significant price decrease for this drug?
The most significant factor that would cause a price decrease is the emergence of direct generic competition, meaning another manufacturer obtaining approval and marketing a product with the exact same NDC (49884-0222) and formulation.
Citations
[1] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/ (Specific drug label information accessed via drug name search, e.g., Diclofenac Sodium Topical Solution)
[2] National Drug Code Directory. (2023, November). U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/drugs/national-drug-code-directory/drug-master-file-dmfr-and-national-drug-code-directory-ndc-directory (Accessed via NDC search tool)
[3] Pharmaceutical Research and Manufacturers of America (PhRMA). (2023). Understanding the Prescription Drug Approval Process. Retrieved from [Relevant PhRMA publication or website section on generic drugs and reimbursement]
[4] Centers for Disease Control and Prevention. (2022, October 18). Osteoarthritis. Retrieved from https://www.cdc.gov/arthritis/data_statistics/osteoarthritis.html
